CTS Corporation

CTS Corporation (CTS) Market Cap

CTS Corporation has a market capitalization of $1.80B.

Price: $62.85

-3.43 (-5.18%)

Market Cap: 1.80B

NYSE · time unavailable

CEO: Kieran O'Sullivan

Sector: Technology

Industry: Hardware, Equipment & Parts

IPO Date: 1980-03-17

Website: https://www.ctscorp.com

CTS Corporation (CTS) - Company Information

Market Cap: 1.80B|Sector: Technology

Company Profile

CTS Corporation manufactures and sells sensors, actuators, and connectivity components in North America, Europe, and Asia. The company provides sensors and actuators for use in passenger or commercial vehicles; connectivity components for telecommunications infrastructure, information technology, and other high-speed applications; switches, temperature sensors, and potentiometers supplied to multiple markets; and fabricated piezoelectric materials and substrates used primarily in medical, industrial, aerospace and defense, and information technology markets. In addition, the company sells and markets its products through its sales engineers, independent manufacturers' representatives, and distributors. CTS Corporation was founded in 1896 and is headquartered in Lisle, Illinois.

Analyst Sentiment

50%
Hold

From 0 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$65.99
▲ +5.00% Upside
Low Target
$47.14
-25% Risk
Median Target
$64.11
2% Mid
High Target
$78.56
25% Max
Consensus
Hold
1 / 4 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,7971,3701,2411,1721,2671,2471,5861,4661,497
Enterprise Value ($M)1,8011,3741,2801,2021,2801,2691,6091,5001,427
Price to Earnings Ratio (P/E)26.0819.9215.7221.4117.1023.3229.1519.6225.44
Price/Earnings-to-Growth Ratio (PEG)14.213.772.2110.997.32
Price to Sales Ratio (P/S)3.239.829.028.189.359.9112.4611.0711.50
Price to Book Ratio (P/B)3.232.462.252.142.302.322.992.762.86
Price to Free Cash Flow Ratio (P/FCF)20.51111.4247.6848.3850.54112.8279.9046.5099.82
Enterprise Value to Sales (EV/Sales)9.859.318.399.4510.0912.6411.3310.97
Enterprise Value to EBITDA (EV/EBITDA)14.6246.0640.9240.1139.8551.5058.9546.6054.08
Debt to Equity Ratio0.030.170.220.260.200.210.220.240.18

CTS Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$62.85
Intrinsic Value$100.29
Market Alignment
Undervalued by 59.6%relative to calculated intrinsic value
9.00%
Exp: 2%2%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.18B
Perpetuity TV Value$3.41B
Discounted TV (PV)$1.44B
TV Weighting %58.9%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CTS CORP (CTS) — Investment Overview

🧩 Business Model Overview

CTS CORP develops and manufactures precision electronic components used inside customer systems, with a strong emphasis on custom and qualified designs. The typical value chain centers on (1) design and engineering collaboration during product qualification, (2) precision manufacturing with tight process controls and quality systems, and (3) continued production tied to ongoing customer programs. Because performance specifications and reliability standards matter at the component level, CTS participates in the customer’s engineering workflow (design-in) rather than selling purely interchangeable off-the-shelf parts.

💰 Revenue Streams & Monetisation Model

Revenue is generated primarily through product sales of precision components (including resistive and interconnect-related offerings), sold into industrial and transportation electronics and other application-driven end markets. Monetisation tends to follow a program-based model: once a design is qualified and incorporated into a customer platform, CTS benefits from repeat orders tied to platform lifecycles. Margin drivers include manufacturing yield and throughput, mix toward higher-spec/custom products, pricing discipline, and the ability to manage material and labor cost volatility. The business model is not subscription-like, but it is characterized by recurring exposure through customer platform replenishment and continued sourcing.

🧠 Competitive Advantages & Market Positioning

CTS’ moat is best described as high switching costs driven by design-in and qualification, reinforced by manufacturing execution and quality credibility. Competitors face friction when attempting to replace qualified components because customers typically require extensive validation, documentation, and reliability testing to change suppliers on mission- or safety-critical electronics. CTS also benefits from process know-how and yield advantages—precision electronics manufacturing is difficult to replicate without proven process capability, and performance requirements create barriers to entry.

  • Switching costs (design-in/qualification): Customer engineering revalidation cycles and risk management make supplier changes slow and costly.
  • Quality/reliability reputation: Components must meet stringent performance criteria, which elevates the importance of demonstrated compliance and process control.
  • Manufacturing know-how: Precision production economics depend on yield, process stability, and scale in specific product categories.

Competitive benchmarking:

  • TE Connectivity and Molex: broad connectivity and components franchises with deep supply chains. Their scale can pressure pricing, but replacing CTS-style qualified precision parts still depends on customer validation and system-level performance.
  • Amphenol: strong in interconnects and engineered solutions; it competes on integration and platform reach. CTS’ advantage is concentrated where precision, reliability, and design-in requirements create less “commoditization.”
  • Industry focus contrast: Larger diversified competitors pursue wide end-market coverage and product breadth, while CTS’ positioning emphasizes precision components where qualification and performance specifications support stickier program relationships.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular increases in electronic content and tighter performance requirements rather than by a single end-market cycle. Key drivers include:

  • Electrification and power management: More advanced power electronics and sensing increase demand for precision passive/precision components and reliable interconnects.
  • Automotive electronics sophistication: Expanded use of driver assistance, vehicle connectivity, and advanced control systems raises requirements for accuracy, stability, and reliability.
  • Industrial automation and instrumentation: Industrial control systems require components that can sustain performance across temperature, vibration, and long operating lifetimes.
  • Medical and other regulated electronics: Reliability and qualification standards support supplier stickiness once designs are validated.
  • Rational replacement and platform refresh cycles: The design-in model can convert engineering wins into multi-year production exposure.

⚠ Risk Factors to Monitor

  • Customer program timing and platform variability: Design wins convert into revenue on qualification and ramp schedules that can shift.
  • Competitive substitution and integration: Customers may pursue integrated solutions or alternative component architectures, which can pressure design-in positions over time.
  • Manufacturing execution and yield: Precision electronics margin depends on stable processes; disruptions can affect output and costs.
  • Concentration and end-market cyclicality: Exposure to transportation and industrial electronics can amplify downturn risk.
  • Supply chain and component availability: Reliance on specialized materials or processing inputs can create cost or availability constraints.

📊 Valuation & Market View

The market typically values CTS as an industrial/technology-enabled manufacturer where cash generation, margin durability, and program longevity are more informative than pure growth. Common valuation approaches in this peer set often rely on EV/EBITDA or P/S supplemented by sensitivity to gross margin, operating leverage, and free-cash-flow conversion. Key valuation drivers include sustaining pricing, mix shift toward higher-spec/custom content, stable yield and utilization, and evidence that engineering wins translate into multi-year production revenue.

🔍 Investment Takeaway

CTS CORP offers a structurally defensible position in precision electronics through design-in switching costs, manufacturing process capability, and quality/reliability credibility. While end markets remain cyclical, the business model’s reliance on qualified programs can support resilience and multi-year visibility when CTS successfully converts engineering participation into long-lived customer sourcing.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CTS.

seekingalpha.com2026-05-29

CTS Eventim AG & Co. KGaA (CEVMY) Q1 2026 Earnings Call Transcript

CTS Eventim AG & Co. KGaA (CEVMY) Q1 2026 Earnings Call Transcript

wsj.com2026-05-29

CTS Eventim Shares Jump After U.S. Tours, Winter Olympics Drive Earnings

The stock was the sharpest riser in the Europe-wide Stoxx 600 index, though shares remained down more than 20% so far this year.

marketbeat.com2026-05-28

CTS Eventim AG & Co. KGaA Q1 Earnings Call Highlights

CTS Eventim AG & Co. KGaA ETR: EVD reported a double-digit increase in first-quarter revenue and earnings, with management pointing to strength in Live Entertainment, resilient Ticketing revenue and an expanding venue business while reiterating its full-year outlook.

globenewswire.com2026-05-26

CTS Corporation to Present at the 16th Annual East Coast IDEAS Investor Conference

LISLE, Ill., May 26, 2026 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS) announced today that it will participate in the 16th Annual East Coast IDEAS Investor Conference June 10-11, 2026 at The Westin Times Square in New York, NY.

gurufocus.com2026-05-22

CTS Corp (CTS) Stock Up 4.0% but GF Value Says Overvalued -- GF Score: 73/100

On May 22, 2026, CTS Corp (CTS) shares rose 4.0% today, closing at $62.32. The stock has performed well recently, reflecting a 52-week range of $36.03 to $62.45

zacks.com2026-05-22

Recent Price Trend in CTS (CTS) is Your Friend, Here's Why

CTS (CTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

zacks.com2026-05-14

CTS (CTS) Is Up 8.33% in One Week: What You Should Know

Does CTS (CTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

globenewswire.com2026-05-14

CTS Corporation Declares a Dividend

LISLE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on July 24, 2026, to shareholders of record at the close of business on June 26, 2026.

seekingalpha.com2026-04-29

CTS Corporation (CTS) Q1 2026 Earnings Call Transcript

CTS Corporation (CTS) Q1 2026 Earnings Call Transcript

zacks.com2026-04-29

CTS (CTS) Q1 Earnings and Revenues Surpass Estimates

CTS (CTS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.44 per share a year ago.

globenewswire.com2026-04-29

CTS Announces First Quarter 2026 Results

LISLE, Ill., April 29, 2026 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of highly engineered solutions that “Sense, Connect and Move,” today announced results for the first quarter of 2026.

gurufocus.com2026-04-28

CTS Corp (CTS) Stock Down 3.0% but Still Overvalued -- GF Score: 76/100

On April 28, 2026, CTS Corp (CTS) shares fell 3.0% to a current price of $54.27. This drop comes amid a 52-week range of $36.03 to $59.66, reflecting a consider

defenseworld.net2026-04-21

CTS (NYSE:CTS) Stock Crosses Above 200 Day Moving Average – Here’s What Happened

CTS Corporation (NYSE: CTS - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $46.72 and traded as high as $55.87. CTS shares last traded at $54.8730, with a volume of 168,498 shares traded. Analyst Upgrades and Downgrades Several research analysts have

globenewswire.com2026-04-14

CTS Corporation Announces Date for First Quarter 2026 Earnings Release and Conference Call

LISLE, Ill., April 14, 2026 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS) will release its earnings for the first quarter 2026 at approximately 8:00 a.m.

zacks.com2026-04-08

CTS or OSIS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Electronics - Miscellaneous Components sector might want to consider either CTS (CTS) or OSI Systems (OSIS). But which of these two companies is the best option for those looking for undervalued stocks?

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CTS reported Q1 2026 revenue of $139.23M and net income of $17.20M (EPS $0.60). On a YoY basis (vs. Q1 2025), revenue rose +10.7% ($139.23M vs. $125.81M) and net income grew +28.6% ($17.20M vs. $13.37M). QoQ, revenue increased slightly by +1.4% ($139.23M vs. $137.27M), while net income declined -12.9% ($17.20M vs. $19.74M). Margins were mixed: gross margin improved modestly (+0.4pp YoY; 39.49% vs. 36.53%), but net margin compressed QoQ (12.35% vs. 14.38%) and was below the stronger QoY profit quarter. Cash generation remained solid. Operating cash flow was $17.30M, producing free cash flow of $12.30M after ~$5.00M capex, and the company returned capital via $8.56M share repurchases and $1.15M dividends. Balance sheet resilience improved: total assets rose to $777.16M and equity increased substantially to $1.11B, while net debt stayed manageable at ~$25.5M. Shareholder returns appear strong given the stock’s price momentum (+49.85% 1-year) and a low dividend yield (~0.08%), with buybacks supporting total return."

Revenue Growth

Good

YoY revenue +10.7% in Q1 2026 ($139.23M vs. $125.81M). QoQ revenue up +1.4% vs. Q4 2025 ($137.27M), indicating modest sequential improvement.

Profitability

Positive

Net income YoY +28.6%, but QoQ net income -12.9% (and net margin down to 12.35% from 14.38%). Gross margin improved YoY to 39.49% from 36.53%, suggesting cost/profit mix improvement.

Cash Flow Quality

Good

Q1 2026 operating cash flow $17.30M and free cash flow $12.30M. Returns of capital were meaningful (repurchases $8.56M; dividends $1.15M). Net income to FCF conversion appears reasonable, with coverage supported by positive FCF.

Leverage & Balance Sheet

Positive

Balance sheet strengthened: total assets up to $777.16M and net debt remained low at ~$25.5M. Equity is high at $1.11B, indicating strong balance-sheet resilience.

Shareholder Returns

Strong

Strong capital appreciation: +49.85% 1-year price change. Dividend yield is low (~0.08%), but buybacks in Q1 ($8.56M) support total shareholder return.

Analyst Sentiment & Valuation

Neutral

Valuation metrics appear rich on earnings (P/E ~19.9) and EV multiples are elevated; no explicit analyst price target was provided in the dataset, limiting upside/downside confirmation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CTS delivered strong Q1 momentum driven by diversification, with sales up 11% YoY to $139M and diversified markets up 18% (book-to-bill 1.1). The key earnings lever was profitability: gross margin expanded 250 bps YoY to 39.5%, alongside adjusted EPS of $0.62 versus $0.44 in 2025. Medical was the primary catalyst—capacity expansion for aesthetics and multiple regional wins in ultrasound and noninvasive aesthetics—supporting expectations for double-digit growth in 2026. Industrial also strengthened materially with bookings up 28% YoY and book-to-bill rising to 1.29. Transportation showed early stability (3% YoY, 7% sequential) while smart actuator qualification progresses. Management remains focused on cost-neutral mitigation for Section 232 and commodity-driven input inflation, though it expects higher cost pressure into Q2. Full-year guidance was narrowed to $560M–$580M sales and $2.35–$2.45 adjusted EPS, with Q2 updates due in July.

AI IconGrowth Catalysts

  • Medical: continued momentum in therapeutic applications; multiple wins across medical ultrasound and a large win for a noninvasive aesthetics application; book-to-bill 1.2
  • Medical: expanded capacity in therapeutics/aesthetics applications based on customer long-term forecasts; management expects double-digit growth year-over-year
  • Industrial: strong 28% year-over-year bookings growth with book-to-bill 1.29 (vs 1.15 in 2025), driven by stabilized OEM demand and recovery in distribution
  • Industrial: wins in flow meter applications, temperature sensing (heat pumps, pool/spa, commercial appliances)
  • Transportation: early stability evidenced by 7% sequential quarter growth; ongoing qualification of next-generation smart actuator across customers
  • Transportation: new business awards including current sensing in Europe and larger award for foot controls with a European OEM; accelerometer added to sensor portfolio via North American OEM win

Business Development

  • Aerospace/Defense: significant underwater hull penetrator business win with potential contract value of ~$20 million over five years
  • Aerospace/Defense: multiple wins for naval sonar and filter applications with several customers
  • Aerospace/Defense: added two new customers for RF filters focused on secure communications, SATCOM connectivity, and anti-jamming applications
  • Transportation: current sensing solution customer win (measures electrical current in vehicle systems)
  • Transportation: foot controls multiple OEM wins across China, Japan, Europe, and North America; current-sensing Europe award and larger foot-controls award with a European OEM in early April
  • Medical: wins across all regions for medical ultrasound and a large win for noninvasive aesthetics application

AI IconFinancial Highlights

  • Sales $139M, up 11% year over year; diversified end markets up 18%; transportation up 3%
  • Book-to-bill 1.1 for the quarter, up 4% vs 2025
  • Adjusted diluted EPS $0.62 vs $0.44 in 2025 (reported also $0.59 vs $0.44 GAAP); Q1 gross margin 39.5%, up 250 bps vs 2025 and +40 bps sequentially
  • Gross margin bridge: operational improvements and favorable end-market mix; foreign currency favorable impact on gross margin of ~$0.7M; additionally noted $3M favorable foreign currency impact on sales
  • Tax rate 20.7% vs expected slightly better due to mix and discrete items; full-year tax rate guidance 21% to 23%
  • Section 232 tariff changes (steel/aluminum), precious metals inflation, and oil-price-driven cost increases (including resin/epoxy) are being managed with target of cost-neutral margin impact; expects more cost pressures from late Q1 into Q2
  • Full-year 2026 guidance narrowed: sales $560M–$580M; adjusted diluted EPS $2.35–$2.45

AI IconCapital Funding

  • Operating cash flow: $17M generated for 2026 year-to-date
  • Cash balance $91M; borrowings $63M on credit facility at end of Q1
  • Debt increased by about $5M in Q1, attributed to lower Q1 operating cash flow (incentive comp timing), continued buybacks, and slightly higher-than-usual capex
  • Share repurchase: purchased 177k shares totaling ~$9M during the quarter; total returned to shareholders $10M via dividends and buybacks in Q1
  • Remaining authorization: $82M remaining under current share repurchase program

AI IconStrategy & Ops

  • Medical capacity expansion primarily tied to aesthetics application; capacity installed ahead of demand based on customer long-term forecasts
  • Transportation: qualification progress on next-generation smart actuator; further enhancements planned later in 2026
  • Capital allocation emphasis: balanced between strategic growth investments in medical and returning cash to shareholders; active pursuit of strategic acquisitions with none announced on this call
  • Cost/margin actions: partnering with customers and suppliers to keep Section 232 and commodity-related cost impacts cost-neutral on margins; monitoring timing differences for short-term margin variability

AI IconMarket Outlook

  • Full-year 2026: sales guidance narrowed to $560M–$580M; adjusted diluted EPS $2.35–$2.45
  • Medical (2026): continued momentum in therapeutics with expanded capacity; expectation of double-digit growth year-over-year
  • Aerospace/Defense: defense bookings expected to pick up in the rest of the year; government funding normalization expected after passage of full-year appropriations bill in February
  • Transportation: geopolitical uncertainty causing expected down production volumes; North American light vehicle ~15M units (IHS), Europe 16M–17M, China ~32M; commercial vehicle demand expected to improve in 2H
  • Commercial vehicle: second-half support expected from rising freight rates, improved spot/contract pricing, and pre-buy event related to EPA 2027
  • Next update timing: Q2 2026 results expected in July

AI IconRisks & Headwinds

  • Aerospace/Defense: potential government funding delays and order lumpiness; management noted book-to-bill could be less than one in a quarter due to funding/ordering timing even if full-year improves
  • Transportation/industrial demand: ongoing monitoring of geopolitical conflicts impacting 2H and potential economic effects; light vehicle volumes forecast to soften in 2026
  • Cost pressures: inflation in precious metals; Section 232 steel/aluminum tariff changes; oil-price-related component cost increases (resin/epoxy, transportation); expects more cost pressures from late Q1 into Q2
  • Supply chain constraints mentioned: petroleum-product supply chain issues (resin) and other components including rare earth metals and semiconductors
  • Margin sustainability: currency impacts can swing both directions; Q1 gross margin benefits partially timing-dependent (including favorable currency in Q1)

Q&A: Analyst Interest

  • Incremental margin/mix durability: Management said diversified-market expansion improves “quality of earnings,” with medical strongest margin profile; industrial is closer to medical than transportation. They emphasized less dispersion across diversified ends and cautioned against over-interpreting short-term incremental math versus ongoing strategy execution and mix effects.
  • Medical capacity expansion specifics: Management clarified capacity expansion primarily relates to the aesthetics application and is enabled by long-term customer forecasts. They noted installs occur ahead of demand to avoid constraints and stated they expect double-digit sales growth year over year, with no current concerns about meeting demand.
  • A&D funding timing and book-to-bill mechanics: Management attributed Q1 softness to a delay in government funding but expected funding pace to pick up in the second half after the appropriations bill passed in February. They also highlighted defense order lumpiness that can produce sub-1.0 book-to-bill in a quarter.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CTS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CTS.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CTS)

© 2026 Stock Market Info — CTS Corporation (CTS) Financial Profile